Dapagliflozin‐induced weight loss affects 24‐week glycated haemoglobin and blood pressure levels

<jats:p>The aim of this study was to investigate the associations between dapagliflozin‐mediated reductions in body weight and reductions in glycated haemoglobin (<jats:styled-content style="fixed-case">HbA1c</jats:styled-content>) and blood pressure. Data were pooled from seven studies evaluating dapagliflozin 10 mg as monotherapy or combination therapy over 24 weeks. Using linear regression to estimate the contribution of weight loss to <jats:styled-content style="fixed-case">HbA1c</jats:styled-content> and blood pressure reductions, the β‐value estimate for <jats:styled-content style="fixed-case">HbA1c</jats:styled-content> (%)/kg was 0.028 (p < 0.0001). Weight loss of 2 kg with dapagliflozin contributed to 6% of the total <jats:styled-content style="fixed-case">HbA1c</jats:styled-content> reduction. For systolic (<jats:styled-content style="fixed-case">SBP</jats:styled-content>) and diastolic blood pressure (<jats:styled-content style="fixed-case">DBP</jats:styled-content>), the β‐value (<jats:styled-content style="fixed-case">mmHg</jats:styled-content>/kg) estimates were 0.606 (p < 0.0001) and 0.253 (p < 0.0001), respectively. Weight loss of 2 kg contributed to 28% of the overall <jats:styled-content style="fixed-case">SBP</jats:styled-content> reduction, and 24% of the overall <jats:styled-content style="fixed-case">DBP</jats:styled-content> reduction. In conclusion, dapagliflozin‐mediated weight loss may contribute to overall reductions in <jats:styled-content style="fixed-case">HbA1c</jats:styled-content> and blood pressure.</jats:p>